AMPA-current antagonism and context-dependent potentiation
Cell-based study · Primary cortical and spinal cord neurons from Wistar rat embryos; recordings 7–14 days after plating. [1]
NBQX inhibited peak AMPA currents in both preparations, but enhanced spinal cord plateau currents at low antagonist concentrations. Cortical concentration-response shifts supported competitive antagonism.
| Endpoint | Reported result | Reference |
|---|---|---|
| Reduction of peak current evoked by 100 μM AMPA with 0.3 μM NBQX | Current reduction 62±7.5%; mean±s.e.mean; n=7 neurons; P<0.001 versus control | [1] |
| Reduction of plateau current evoked by 100 μM AMPA with 0.3 μM NBQX | Current reduction 42±9.6%; mean±s.e.mean; n=7 neurons; P<0.001 versus control | [1] |
| Reduction of peak current evoked by 100 μM AMPA with 0.3 μM NBQX | Current reduction 34±3%; mean±s.e.mean; n=20 neurons; P<0.001 versus control | [1] |
| Spinal cord plateau current with 100 μM AMPA and 0.3 μM NBQX | Percentage of control current 117±4%; mean±s.e.mean; n=20 neurons; P<0.001 versus control | [1] |
| Competitive antagonism of cortical AMPA plateau responses | pKi; Schild slope pKi=6.6; slope=0.92 | [1] |
| Spinal cord plateau-current response to 500 μM AMPA across NBQX concentrations | Concentration-dependent effect Potentiation at 0.1–1 μM NBQX; maximum increase 40±7% at 1 μM (n=7; P<0.001); depression significant versus control at ≥2.5 μM (P<0.05). | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.3 μM NBQX with 100 μM AMPA (Figure 1); 0.1 and 0.3 μM NBQX in cortical AMPA concentration-response analysis (Figure 2A); 0.1–3 μM NBQX with 500 μM AMPA (Figure 2C).
- Exposure duration
- Figure 1: 5 s NBQX pretreatment, then 15 s AMPA application with NBQX continuously present; 40 s between agonist applications.
- Method
- Whole-cell patch clamp at −60 mV and room temperature (20–24°C); semi-rapid compound application.
- Vehicle
- NBQX stock in artificial balanced salt solution (ABSS); AMPA stock in 50 mM NaOH, diluted for recording.
- Co-treatment
- AMPA challenge; 0.2 μM tetrodotoxin in recording medium to suppress regenerative sodium currents and synaptic potentials.
- Reported limits
- NBQX salt/hydration state, lot and purity not specified; no separately reported vehicle-only response in the selected experiment. Figure 1 application duration is not assigned to every Figure 2 condition.
Methods and source locations
Compound reported in the paper: NBQX; Compound label in the paper: NBQX, gift from Novo Nordisk
Results apply to the authors’ reported NBQX preparation and stated model. No salt conversion, Adooq provenance or lot-level performance claim.
Results, Responses mediated by AMPA receptors; Figures 1A–C and 2A–C and captions; Methods, Cell culture, Electrophysiological recordings, application of compounds, Data analysis
Reduction of peak current evoked by 100 μM AMPA with 0.3 μM NBQX: Current normalized to the AMPA response without NBQX; two-tailed t-test. — Results, first AMPA-response paragraph; Figure 1A,C and caption
Reduction of plateau current evoked by 100 μM AMPA with 0.3 μM NBQX: Whole-cell recording; control is AMPA without NBQX. — Results, first AMPA-response paragraph; Figure 1A,C and caption
Reduction of peak current evoked by 100 μM AMPA with 0.3 μM NBQX: Whole-cell recording; control is AMPA without NBQX. — Results, first AMPA-response paragraph; Figure 1B,C and caption
Spinal cord plateau current with 100 μM AMPA and 0.3 μM NBQX: Normalized to the AMPA-alone plateau current; this is enhancement to 117%, not a 117% increase. — Results, first AMPA-response paragraph; Figure 1B,C and caption
Competitive antagonism of cortical AMPA plateau responses: Parallel rightward concentration-response shifts at 0.1 and 0.3 μM NBQX; functional Schild analysis, not radioligand binding IC50. — Results, AMPA concentration-response paragraph; Figure 2A caption
Spinal cord plateau-current response to 500 μM AMPA across NBQX concentrations: Mean±s.e.mean; normalized to 500 μM AMPA alone. Cortical responses were depressed over the same antagonist range without potentiation. — Results, end of AMPA concentration-response paragraph; Figure 2C and caption